CG
TXMD icon

Cutler Group’s TherapeuticsMD TXMD Stock Holding History

Cutler Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100
Closed – – 4335
2023
Q2 		$0 Hold
100
– – ﹤0.01% 4190
2023
Q1 		$0 Buy
+100
New +$480 ﹤0.01% 4741
2022
Q4 		– Sell
-600
Closed -$3K – 5241
2022
Q3 		$3K Buy
+600
New +$4.86K ﹤0.01% 4049
2019
Q1 		– Sell
-1
Closed – – 4779
2018
Q4 		$0 Hold
1
– – ﹤0.01% 4608
2018
Q3 		$0 Hold
1
– – ﹤0.01% 4715
2018
Q2 		$0 Sell
1
-10
-91% -$3.06K ﹤0.01% 4910
2018
Q1 		$2K Sell
11
-286
-96% -$80.2K ﹤0.01% 3849
2017
Q4 		$89K Buy
297
+248
+506% +$69K ﹤0.01% 1451
2017
Q3 		$12K Sell
49
-939
-95% -$271K ﹤0.01% 3659
2017
Q2 		$260K Buy
988
+861
+678% +$216K 0.01% 1088
2017
Q1 		$45K Sell
127
-370
-74% -$115K ﹤0.01% 2527
2016
Q4 		$143K Buy
497
+496
+49,600% +$154K 0.01% 1585
2016
Q3 		$0 Sell
1
-56
-98% -$20.5K ﹤0.01% 7394
2016
Q2 		$24K Sell
57
-94
-62% -$38.7K ﹤0.01% 3168
2016
Q1 		$48K Buy
151
+144
+2,057% +$49.1K ﹤0.01% 2382
2015
Q4 		$3K Buy
+7
New +$2.58K ﹤0.01% 5382

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's TXMD Position: Q3 2023 in Review

Cutler Group sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 100 shares.

Cutler Group first reported a position in TXMD in Q4 2015 and held it in 16 quarters. The position peaked at $260K in Q2 2017. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Cutler Group reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 100 TherapeuticsMD shares in Q3 2023.
  • Cutler Group first reported a position in TherapeuticsMD in Q4 2015 and held it in 16 quarters.
  • Cutler Group's TherapeuticsMD position peaked at $260K in Q2 2017.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.